<div id="readability-page-1"><div id="parent_top_div"><p>Sun Pharmaceutical Industries on Thursday said it has settled an antitrust litigation in the US entailing a payment of $200 million.</p> <p>  The subsidiaries of the company, Sun Pharmaceutical Industries, Inc. (SPII) and Taro Pharmaceuticals USA, Inc. have signed a settlement agreement with the End Purchaser Plaintiffs in the In re Generic Pharmaceuticals Pricing Antitrust Litigation in the Eastern District of Pennsylvania, US, the Mumbai-based drugmaker said in a regulatory filing.</p> <p>  &#34;Under the terms of the settlement agreement, the subsidiaries will make an aggregate payment of $200 million in exchange for a full release of all claims asserted against them in the End Purchaser Action by the settlement class members,&#34; it added.</p> <p>  The settlement amounts may be reduced if more than a certain percentage of the total insured class members opt out of the putative class, the company stated.</p> <p>The settlement agreement is subject to court approval, it added.</p></div></div>

Taro藥業

<p>陽光製藥工業公司已就一起美國反壟斷案件達成 2 億美元的和解。該公司的子公司 SPII 和 Taro Pharmaceuticals USA 與 “仿製藥定價反壟斷訴訟案” 中的最終購買者原告達成了協議。和解包括對他們的所有索賠的全面解除，但如果大量投保的集體成員選擇退出，支付金額可能會減少。該協議尚待法院批准</p>

太陽製藥通過達成 2 億美元協議解決了美國的反壟斷案件